Stocks · News reference
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.